WASHINGTON — Congressional progressives secured a series of changes to the sweeping drug pricing bill the House is considering this week in return for dropping a threat to upend the vote altogether.
The changes do not significantly change Speaker Nancy Pelosi’s reforms, which would let Medicare negotiate the prices of certain high-cost drugs. Their tweaks include a slight increase in the number of drugs that would be negotiated each year, from 35 to 50, and a provision that will pave the path, but not explicitly enact, another policy meant to block drug makers from hiking their prices more than inflation.
The tweaks seem to have finally placated the Congressional Progressive Caucus, a band of liberal Democrats that has waged war against Pelosi and her staff for nearly a year over what they saw as an inappropriately modest drug pricing reform.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect